Lung cancer research and treatment: global perspectives and strategic calls to action

Lung cancer remains a critical public health issue, presenting multifaceted challenges in prevention, diagnosis, and treatment. This article aims to review the current landscape of lung cancer research and management, delineate the persistent challenges, and outline pragmatic solutions. Global exper...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Annals of oncology 2024-12, Vol.35 (12), p.1088-1104
Hauptverfasser: Meyer, M.-L., Peters, S., Mok, T.S., Lam, S., Yang, P.-C., Aggarwal, C., Brahmer, J., Dziadziuszko, R., Felip, E., Ferris, A., Forde, P.M., Gray, J., Gros, L., Halmos, B., Herbst, R., Jänne, P.A., Johnson, B.E., Kelly, K., Leighl, N.B., Liu, S., Lowy, I., Marron, T.U., Paz-Ares, L., Rizvi, N., Rudin, C.M., Shum, E., Stahel, R., Trunova, N., Bunn, P.A., Hirsch, F.R.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Lung cancer remains a critical public health issue, presenting multifaceted challenges in prevention, diagnosis, and treatment. This article aims to review the current landscape of lung cancer research and management, delineate the persistent challenges, and outline pragmatic solutions. Global experts from academia, regulatory agencies such as the Food and Drug Administration (FDA) and the European Medicines Agency (EMA), the National Cancer Institute (NCI), professional societies, the pharmaceutical and biotech industries, and patient advocacy groups were gathered by the New York Lung Cancer Foundation to review the state of the art in lung cancer and to formulate calls to action. Improving lung cancer management and research involves promoting tobacco cessation, identifying individuals at risk who could benefit from early detection programs, and addressing treatment-related toxicities. Efforts should focus on conducting well-designed trials to determine the optimal treatment sequence. Research into innovative biomarkers and therapies is crucial for more personalized treatment. Ensuring access to appropriate care for all patients, whether enrolled in clinical trials or not, must remain a priority. Lung cancer is a major health burden worldwide, and its treatment has become increasingly complex over the past two decades. Improvement in lung cancer management and research requires unified messaging and global collaboration, expanded education, and greater access to screening, biomarker testing, treatment, as well as increased representativeness, participation, and diversity in clinical trials. •Lung cancer research and treatment require strong global collaborations.•Tobacco cessation and screening programs need better implementation, focusing on the at-risk population for screening.•Dedicated funding for treatment and research is needed to guarantee access for underserved communities.•Improved trial design requires early collaboration with academia, industry, organizations, and regulatory authorities.•New technologies and novel biomarkers could help personalize treatment to improve efficacy and lower toxicity.
ISSN:0923-7534
1569-8041
1569-8041
DOI:10.1016/j.annonc.2024.10.006